Reuters: Global Markets: AcelRx pain treatment meets late-stage study goal

Reuters: Global Markets Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

AcelRx pain treatment meets late-stage study goal Mar 4th 2013, 23:25 Mon Mar 4, 2013 6:25pm EST (Reuters) - AcelRx Pharmaceuticals Inc said its experimental drug-device combination for post-operative pain met the main goal of a late-stage study on patients who have undergone major open abdominal surgery. AcelRx shares jumped 10 percent to $5.49 after the bell on Monday. The top-line results reported from a 178-patient study of AcelRx's sublingual Sufentanil NanoTab PCA system showed that the patient-controlled drug-device combination helped reduce pain significantly compared with a placebo, the company said.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions